BioMerieux (BioMerieux) Accounts Payable & Accrued Expense : $760 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is BioMerieux Accounts Payable & Accrued Expense?

BioMerieux's quarterly accounts payable & accrued expense declined from Dec. 2022 ($732 Mil) to Jun. 2023 ($308 Mil) but then increased from Jun. 2023 ($308 Mil) to Dec. 2023 ($760 Mil).

BioMerieux's annual accounts payable & accrued expense increased from Dec. 2021 ($706 Mil) to Dec. 2022 ($732 Mil) and increased from Dec. 2022 ($732 Mil) to Dec. 2023 ($760 Mil).

BioMerieux Accounts Payable & Accrued Expense Historical Data

The historical data trend for BioMerieux's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Accounts Payable & Accrued Expense Chart

BioMerieux Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

586.11

704.14

705.99

731.99

759.65

BioMerieux Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															705.99	293.87	731.99	307.80	759.65

BioMerieux Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

BioMerieux (BioMerieux) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (OTCPK:BMXMF) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

BIMp:UK 0RUG:UK BIM:France EYWN:Germany BIM:Austria

Address

Marcy l’Etoile, Lyon, FRA, 69280

Website

http://www.biomerieux.com

BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (BioMerieux) Headlines

From GuruFocus

bioM�rieux Introduces GENE-UP� ENVIROPRO�

By PRNewswire PRNewswire • 02-02-2023

French multidisciplinary consortium ARPEGE awarded public funding of close to �9 million to fight antibiotic resistance

By PRNewswire PRNewswire • 01-06-2022